Soluble urokinase plasminogen activator receptor and functionally relevant coronary artery disease: a prospective cohort study.

Autor: Walter JE; Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.; Department of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Amrein MLF; Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland., Schäfer I; Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland., Zimmermann T; Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland., Lopez-Ayala P; Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland., Boeddinghaus J; Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland., Twerenbold R; Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.; University Heart & Vascular Center Hamburg, Hamburg, Germany., Puelacher C; Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland., Nestelberger T; Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.; Vancouver General Hospital, University of British Columbia, Vancouver, Canada., Wussler D; Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.; Universitäts-Herzzentrum Bad Krozingen, Bad Krozingen, Germany., Honegger U; Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland., Badertscher P; Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland., Eugen-Olsen J; Clinical Research Centre, Copenhagen University Hospital Hvidovre, Copenhagen, Denmark., Koechlin L; Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.; Department of Cardiac Surgery, University Hospital Basel, University of Basel, Basel, Switzerland., Fahrni G; Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland., Jeger R; Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland., Kaiser C; Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland., Zellweger M; Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland., Mueller C; Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.
Jazyk: angličtina
Zdroj: Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals [Biomarkers] 2022 May; Vol. 27 (3), pp. 278-285. Date of Electronic Publication: 2022 Feb 15.
DOI: 10.1080/1354750X.2022.2038269
Abstrakt: Background: Soluble urokinase plasminogen activator receptor (suPAR) is an emerging biomarker associated with anatomical CAD burden and cardiovascular outcomes including myocardial infarction (MI) and death. We aimed to validate previous findings of the prognostic value of suPAR and to evaluate its diagnostic potential for functional relevant CAD (fCAD).
Methods: Consecutive patients with suspected fCAD were enrolled. Adjudication of fCAD was performed blinded to suPAR concentrations by myocardial perfusion single-photon emission tomography (MPI-SPECT) and coronary angiography. Prognostic outcome measures included all-cause death, cardiovascular death, and incident MI during 2-year follow-up.
Results: Among consecutive 968 patients, suPAR concentrations were higher in patients with fCAD compared to those without (3.45 vs. 3.20 ng/mL, p  = 0.007), but did not provide acceptable diagnostic accuracy (area under the curve [AUC]: 0.56, 95%CI 0.52-0.60). SuPAR correlated with high-sensitivity cardiac-troponin T (Spearman's rho ( ρ ) 0.393, p  < 0.001), NT-proBNP ( ρ  = 0.327, p  < 0.001), age ( ρ  = 0.364, p  < 0.001) and very weakly with coronary atherosclerosis ( ρ  = 0.123, p  < 0.001). Prognostic discrimination of suPAR was moderate for cardiovascular death (AUC = 0.72, 95%CI 0.62-0.81) and all-cause death (AUC = 0.72, 95%CI 0.65-0.79) at 2-years. SuPAR remained a significant predictor for all-cause death in multivariable Cox regression (HR = 1.96, p  = 0.001).
Conclusions: SuPAR was an independent predictor of all-cause death, without diagnostic utility for fCAD.
Clinical Trial Registration: NCT01838148.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje